

Prodrug Design by Computation Methods to Treat Parkinson's Disease

Halla T. Mohammed, and Abbas A-Ali Drea

University of Babylon, College of Science, Department of Chemistry, Iraq, Hilla

Abstract: Simulation studies of nine compounds have been suggested to treat Parkinson's disease using quantum calculation methods. Geometrical properties and vibration spectra have been calculated for all suggested chemical compounds to estimate the best for Parkinson's disease treatment by calculating the potential energy surface, atomic charge, bond length, bond angle, dipole moment, electrostatic potential and molecular orbital energy with energy gap. The calculations show that the M-6-SPhe compound has the structure and chemical properties of an ideal value compared to other suggested chemical compounds. Also, it has the lowest value of dipole moment equal to 3.028 Debye, and it has the highest value of the energy gap equal to 8.786 eV compared to the other chemical compounds suggested.

Keywords: Semi-empirical method, DFT, Parkinson's disease, Prodrug.

INTRODUCTION

Studies have proven Parkinson's disease PD was widespread more than 4 million people worldwide suffer from Parkinson's. The number of cases was rising where about 50,000 new cases are recorded each year[1]. This disease was considered the second most common neurodegenerative disease after Alzheimer's disease. This disease causes, tremor, bradykinesia (slowed movement), and rigidity. The risk of this disease is the process of PD in your body may start 5 to 20 years before the first symptoms are recognized[2]. The symptoms of PD result from the die or weakness of the substantianigra (literally "black substance"). Usually, these cells produce a chemical messenger called Dopamine, which transmits signals inside the brain to produce smooth and easy physical movements[3,4].

The most effective treatment for PD is give a modified amino acid known as L-DOPA, which is converted to dopamine in the brain. L-dopa (3, 4-dihydroxy-L-phenylalanine) is a chemical compound synthesis in the human body made from L-Tyrosine, in some cases from L-phenylalanine. L-DOPA, a dopamine precursor, either alone or in combination with an aromatic amino acid decarboxylase inhibitor (carbidopa, benserazide) is the most effective drug for the treatment of PD, because they able to cross the blood-brain barrier, whereas Dopamine itself cannot [5-8].

*Corresponding author: aadreab22@yahoo.com

Most symptomatic medications used in the treatment are: Levodopa, Dopamine agonists, MAO-B inhibitors, Amantadine, Anticholinergic, and COMT-inhibitors. These current treatments only reduce the symptoms of the PD for a limited period, most of these drugs preparing as a prodrugs [9]. Prodrug is a very versatile strategy to increase the Interest of biologically active compounds and decrease their associated toxicity. First described by Adrien Albert in the late 1958 [10]. It is a medication or compound which inactive, but which can be transformed by enzymatic to release the active parent drug in the human body. The aim of prodrug manufacturing through chemically modified derivatives of active drug compounds to hide unwanted drug properties, like low solubility in lipid or water, low selectivity, chemical instability, toxicity, to reduce side effects, and to enhance the absorption, distribution [11-13].

The present study tends to treat for Parkinson's disease. Different prodrugs were suggested to find the best prodrug to treat Parkinson's disease theoretically through the quantum calculation processes of the electronic and geometrical structure by using PM3 of semi-empirical calculations and DFT minimal STO-3G.

COMPUTATIONAL DETAILS

Theoretical calculations were completed by using the computational implemented in the Hyperchem Version 8.0.9 program [14-15]. Geometry optimization, electronic energies, heat of formation for different prodrugs suggested have been optimized at semi empirical method and DFT- STO-3G. The highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) were studied to calculate the energy gap (ΔE) [16, 17]. Bond lengths, bond angle, and the charge of atoms have been calculated at semi-empirical method, PM3 level [18].

RESULTS AND DISCUSSION

Several prodrugs of medication treatment for Parkinson's disease have been suggested and study the geometrical structure of all prodrugs. Where, sugar molecules include fructose, glucose, and mannose were linked to the amino group of the Phenylaniline linked to a different position (C1, C3, and C6) of the sugar through succinyl linker, to be lipophilic derivatives of Phenylaniline in order to transfer through the blood-brain barrier, which have selective permeability [19]. Fig. 1 represent the geometrical structure of suggested prodrug.

The energies of bond stability of different prodrug calculated by a semi empirical PM3 method and shown in Table 1. From Table 1 note that N-C2 4 bond in M-3-SPhe, M-6-SPhe, and F-3-SPhe molecules are more stable than in other probable drug due to require 80.1, 79.8, and 80 kCal/mol respectively of bond dissociation energy.

Potential energy stability of N-C2 4-O2 angle of all prodrugs were calculated, and represented in Table 2. From Table 1 note that N-C2 4-O2 angle in the M-6-SPhe molecule was requires 2950 kCal/mol higher value dissociation energy than other prodrugs. So this angle is more stability in M-6-SPhe than in other prodrugs.




Figure 1: Chemical structure of suggested prodrugs

Table 1: Potential energy stability and dissociation of N-C₂ bond length calculate at semi empirical PM3 method

| | <i>Bond length A°</i> | <i>Potential energy stability kCal/mol)</i> | <i>Potential energy dissociation kCal/mol)</i> | <i>Bond dissociation Energy kCal/mol)</i> |
|-----------------|---------------------------|---|--|---|
| M-1-SPhe | 1.516 | -5630.52 | -5570.62 | 59.9 |
| M-3-SPhe | 1.521 | -5630.52 | -5550.42 | 80.1 |
| M-6-SPhe | 2.896 | -5660.40 | -5580.60 | 79.8 |
| G-1-SPhe | 1.520 | -5620.52 | -5550.42 | 70.1 |
| G-3-SPhe | 1.525 | -5630.53 | -5570.53 | 60.0 |
| G-6-SPhe | 1.533 | -5640.53 | -5570.23 | 70.3 |
| F-1-SPhe | 1.881 | -5320.28 | -5320.38 | -0.1 |
| F-3-SPhe | 2.800 | -5380.30 | -5300.30 | 80 |
| F-6-SPhe | 1.534 | -5360.53 | -5300.44 | 60.09 |

Table 2
Potential energy stability of N-C2 4=O2 bond angle calculates at semi empirical PM3 method

| Probables | Bond angle stability (degree) | Potential energy stability (kCal/mol) | Potential energy dissociation (kCal/mol) | Angle dissociation Energy (kCal/mol) |
|-----------|-------------------------------|---------------------------------------|--|--------------------------------------|
| M-1-SPhe | 114.115 | -56340.0 | -55870.0 | 470 |
| M-3-SPhe | 114.670 | -56340.0 | -55870.0 | 470 |
| M-6-SPhe | 83.443 | -56620.0 | -53670.0 | 2950 |
| G-1-SPhe | 116.615 | -56250.0 | -56070.0 | 180 |
| G-3-SPhe | 115.589 | -56350.0 | -56070.0 | 280 |
| G-6-SPhe | 114.134 | -56410.0 | -54670.0 | 1740 |
| F-1-SPhe | 111.297 | -53150.0 | -52670.0 | 480 |
| F-3-SPhe | 109.531 | -53830.0 | -53850.0 | -20 |
| F-6-SPhe | 117.850 | -53650.0 | -52270.0 | 1380 |

Table 3 represents energetic properties of proposed prodrugs. M-6-SPhe has -132291.816 kCal/mol total energy less energy than other prodrugs, so it considers favorite[20], and it has -400.534 kCal/mol heat of formation, That means this formation reaction from initial elements is exothermic, so it needs the amount of energy in order to decompose to the initial elements. This means that the M-6-SPhe compound is more stable than other probable[21]. HOMO energy for highest occupied molecular orbital, it shows the ability the molecule to the loss of electrons, since whenever the value was higher became easy to loss the electrons in the pharmaceutical compounds, While LUMO energy for lowest unoccupied molecular orbital, it shows the ability the molecule to acquire electrons, since whenever the value was less became easy to acquire electrons[22]. Therefore the compound has the highest value of the energy gap is the most effective in the pharmaceutical compounds. The M-6-SPhe compound has 8.786 eV energy gap higher than other probable. HOMO, and LUMO are show at two and three dimensions in Fig 2. The M-6-SPhe compound has the lowest value of dipole moment equal to 3.028 Debye, So become more lipophilic than other prodrugs.

Table 3
The properties of energy for all pordrugs calculated by a semi empirical PM3 method

| Probable drug | Total energy kCal/mol | ZPE kCal/mol | Heat of Formation kCal/mol | Molecular orbital energy | | | Dipole moment |
|---------------|-----------------------|--------------|----------------------------|--------------------------|-----------|-----------------------|---------------|
| | | | | HOMO (eV) | LUMO (eV) | E _{gab} (eV) | |
| M-1-SPhe | -132263.793 | 273.082 | -372.511 | -9.672 | -1.520 | 8.152 | 9.862 |
| M-3-SPhe | -132261.339 | 272.472 | -370.057 | -9.538 | -1.281 | 8.257 | 10.750 |
| M-6-SPhe | -132291.816 | 273.472 | -400.534 | -10.067 | -0.241 | 8.786 | 3.028 |
| G-1-SPhe | -132257.100 | 271.714 | -365.818 | -9.445 | -1.282 | 8.163 | 12.130 |
| G-3-SPhe | -132264.071 | 272.339 | -372.789 | -9.463 | -1.276 | 8.187 | 10.850 |
| G-6-SPhe | -132273.191 | 273.846 | -381.909 | -10.168 | -1.447 | 8.721 | 9.603 |
| F-1-SPhe | -130738.184 | 244.671 | -261.216 | -8.592 | -3.716 | 4.876 | 10.580 |
| F-3-SPhe | -130808.221 | 244.917 | -331.253 | -10.122 | -1.124 | 8.998 | 4.600 |
| F-6-SPhe | -130789.970 | 246.313 | -313.009 | -9.801 | -1.877 | 7.924 | 8.929 |




Figure 2: HOMO and LUMO levels of M-6-SPhe

Energy properties of the most stability compound M-6-SPhe calculated by DFT- STO-3G level of theory and semi empirical PM3 method and listed in Table 4. From Table 3-8 notice there are different in a value between tow method, because DFT method more accurate than semi empirical methods. The semi empirical method depends on empirical values and neglect of a large number of electron integrals. However, it was considered an important method due to require a short time for calculation. Also, it was able to calculate heat formation, while DFT it self cannot [23].

Chemical effectiveness of M-6-SPhe has been studied include electronic potential, total charge density is shown in Fig 3. Fig 3 shows that the regions of high electron density on the oxygen atom of the red color, while regions with low electron density of the atoms of hydrogen represented green color. The electronic density centered on the oxygen and nitrogen atoms because they contain a loan pair, also notes that the hydrogen atoms are suffer decrease electronic density due to high electrostatic of nitrogen and oxygen[24].

Table 4
Energy properties of M-6-SPhe calculated by DFT- STO-3G level of theory and semi empirical PM3 methods

| | | <i>DFT</i> | <i>Semi empirical PM3</i> |
|--------------------------------|--------------------------|-------------|---------------------------|
| Total energy (kCal/mol) | | -339169.320 | -132291.816 |
| ZPE kCal/mol) | | 335.188 | 273.472 |
| Heat of Formation kCal/mol | | - | -400.534 |
| Molecular orbital energy | HOMO (eV) | -7.629 | -10.067 |
| | LUMO (eV) | 1.538 | -0.241 |
| | ΔE_{gab} (eV) | 9.167 | 8.786 |
| Dipole moment | | 2.630 | 3.028 |
| Time of calculation (hours) | | 739:11:36 | 0:11:25 |




Figure 3: Physical properties of geometry optimization M-6-SPhe calculated at semi empirical method

CONCLUSION

The M-6-SPhe prodrug is better than other suggested prodrugs due to: The relaxation energy value of the geometrical optimization structure is less than other suggested structures. It has the highest value of the energy gap, so it is the most stable in the pharmaceutical compounds. It has the lowest value of the dipole moment, so become more lipophilic than other prodrugs to be able to cross the blood-brain barrier.

References

- [1] B. R. Ritz, A. D. Manthripragada, S. Costello, S. J. Lincoln, M. J. Farrer, M. Cockburn, J. Bronstein, "Dopamine transporter genetic variants and pesticides in Parkinson's disease", *Environ Health Perspect*. 2009. Vol. 117. No. 6. P.964-969.
- [2] Z. X. Zhang, and G. C. Roman, " Worldwide occurrence of Parkinson's disease: an updated review", *Neuroepidemiology*.1993. Vol. 12. No. 4. P. 195-208.
- [3] J. H. Bower, D. M. Maraganore, B. J. Peterson, S. K. McDonnell, J. E. Ahlskog, and W. A. Rocca, " Head trauma preceding PD: a case-control study", *Neurology*.2003. Vol. 60. No. 10. P 1610-1615.
- [4] P. M. Abou-Sleiman, M. M Muqit, and N. W. Wood, "Expanding insights of mitochondrial dysfunction in Parkinson's disease", *Nat Rev Neurosci*.2006. Vol.7. No. 3. P. 207-219.
- [5] S. A. Inamdar, S. N. Surwase, S. B. Jadhav, V. A. Bapat, and J. P. Jadhav, " Statistically optimized biotransformation protocol for continuous production of L-DOPA using *Mucunamonosperma* callus culture", *SpringerPlus*, 2013. Vol. 2. No. 570. P. 2-9.
- [6] B. Kobe, I. G. Jennings, C. M. House, B. J. Michell, K. E. Goodwill, B. D. Santarsiero, R. C. Stevens, R. G. H. Cotton, and B. E. Kemp, "Structural basis of autoregulation of phenylalanine hydroxylase", *Nat. Struct. Mol. Biol.*, 1999. Vol. 6. No. 5. P. 442-448.
- [7] J. Renson, H. Weissbach, and S. Udenfriend, "Hydroxylation of tryptophan by phenylalanine hydroxylase", *J. Biol. Chem.*, 1962. Vol. 237. No.7.P. 2261- 2264.
- [8] P. Manivasagan, J. Venkatesan, K. Sivakumar, and S. K. Kim, " Actinobacterialmelanins: current status and perspective for the future", *World J MicrobiolBiotechnol*. 2013. Vol.29. No. 10. P. 1737-1750.
- [9] M. J. Farrer, Nature Publishing Group, " Genetics of Parkinson disease: paradigm shifts and future prospects", *Review*. 2006. Vol.7. P. 306- 318.
- [10] A. Albert, "Chemical aspects of selective toxicity", *Nature*. 1958. Vol. 182. No. 4633. P. 421-422.
- [11] K. M. Huttunen, and J. Rautio, "Prodrugs - An Efficient Way to Breach Delivery and Targeting Barriers", *Current Topics in Medicinal Chemistry*. 2011. Vol. 11. No. 18. P. 2265- 2287.
- [12] J. B. Zawilska, J. Wojcieszak, A. B. Olejniczak, "Prodrugs: A challenge for the drug development", *Pharmacological Reports.*, *Review*. 2013. Vol. 65. No. 1. P. 1-14.
- [13] R. V. Ghadage, "PRODRUG DESIGN FOR OPTIMIZED DRUG DELIVERY SYSTEMS", *Journal of Biological & Scientific Opinion.* , *Review*.2013. Vol. 1. No. 3. P. 255-262.
- [14] I. Sheikhsheoie and S. Saeednia, "Synthesis, characterization and nonlinear optical properties of four novel schiff base Compounds", *The Arabian Journal for Science and Engineering*.2010. Vol. 35. No. 1A. P. 53-60.
- [15] A. A. Drea, S. A. Naman, and B. R. Jaffer, "Theoretical Degradation Study of Methomy1", *Journal of Applicable Chemistry*.2012. Vol. 1. No. 1. P. 125-136.
- [16] H. Adnan, S. A. Aowda, and A. A. Drea, "Simulation Study of alkylation reaction of resorcinol", *Journal of Applicable Chemistry*vol.2014. Vol. 3. No.6. P. 2365-2371.
- [17] A. A. Drea, and N. Izet, "Estimation Study of Mechanism and Kinetic for the Reactions of Ethane in Vacuum Using DFT", *Journal of photocatalysis science*.2012. Vol. 3. No. 2. P. 49-59.
- [18] A. A. Hussein, and A. A. Drea, "Study of Ozone Depletion by Halon-2402 in Stratospheric Layer Using Quantum Calculation Methods", *Journal of Applicable Chemistry*.2012. Vol. 1. No. 2. P. 319-329.
- [19] A. D. Stefano, P. Sozio and L. S. Cerasa, "Antiparkinson Prodrugs", *Review, Journal Molecules*. 2008. Vol. 13. No. 1. P.46-68.
- [20] A. H. Saeed, *Principels of Chemical Reaction Rates*, Basrah University.1988. P.123.
- [21] P. Atkins, "Physical Chemistry" Oxford. 2001. P. 351.
- [22] H. H. Jawad, Msc. Thesis, Baghdad University, Iraq 2008.
- [23] R. Pariser and R. G. Parr, "A Semi Empirical Theory of the Electronic Spectra and Electronic Structure of Complex Unsaturated Molecules. I", *J. Chem. Phys*, 1953. Vol. 21. No. 3. P. 466.
- [24] A.A. Drea, N. Izet, "Mechanism and Kinetic of Free Radical Reactions for Propane Using theoretical Calculations", *J. Chem. Eng*.2012. Vol. 6. P. 563-573.